These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 18237476)

  • 21. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
    Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
    J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.
    Gidal BE; Anderson GD; Rutecki PR; Shaw R; Lanning A
    Epilepsy Res; 2000 Nov; 42(1):23-31. PubMed ID: 10996503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug treatment of epilepsy in elderly people: focus on valproic Acid.
    Stephen LJ
    Drugs Aging; 2003; 20(2):141-52. PubMed ID: 12534314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproate population pharmacokinetics in children.
    Serrano BB; García Sánchez MJ; Otero MJ; Buelga DS; Serrano J; Domínguez-Gil A
    J Clin Pharm Ther; 1999 Feb; 24(1):73-80. PubMed ID: 10319910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of therapeutic drug monitoring of antiepileptic drugs.
    Irshaid YM; Hamdi AA; Al Homrany M
    Int J Clin Pharmacol Ther; 2003 Mar; 41(3):126-31. PubMed ID: 12665161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
    Jiao Z; Shi XJ; Zhao ZG; Zhong MK
    J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of valproate in Mexican children with epilepsy.
    Correa T; Rodríguez I; Romano S
    Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital.
    Castro-Gago M; Eirís-Puñal J; Novo-Rodríguez MI; Couceiro J; Camiña F; Rodríguez-Segade S
    J Child Neurol; 1998 Nov; 13(11):546-9. PubMed ID: 9853647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS.
    Nakajima Y; Ito T; Maeda Y; Ichiki S; Kobayashi S; Ando N; Hussein MH; Kurono Y; Sugiyama N; Togari H
    Brain Dev; 2011 Nov; 33(10):816-23. PubMed ID: 21196091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic valproic acid and coantiepileptic drug therapy and incidence of increases in serum liver enzymes.
    Haidukewych D; John G
    Ther Drug Monit; 1986; 8(4):407-10. PubMed ID: 3103262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.
    Haidukewych D; John G; Zielinski JJ; Rodin EA
    Ther Drug Monit; 1985; 7(3):290-4. PubMed ID: 3931312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
    EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
    Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carnitine deficiency: Risk factors and incidence in children with epilepsy.
    Fukuda M; Kawabe M; Takehara M; Iwano S; Kuwabara K; Kikuchi C; Wakamoto H; Morimoto T; Suzuki Y; Ishii E
    Brain Dev; 2015 Sep; 37(8):790-6. PubMed ID: 25547040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
    Zeng K; Wang X; Xi Z; Yan Y
    Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.